KRAS and pancreatic neoplasm: These mutant-specific KRAS-targeted drugs, including Sotorasib, Adagrasib, and MRTX1133, provide new hope for patients suffering from highly malignant tumors driven by KRAS mutations such as pancreatic cancer, lung cancer, and colon cancer.